VYGR — Voyager Therapeutics Share Price
0.000.00%
Last trade - 00:00- $174.45m
- -$92.23m
- $80.00m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.58 | ||
| Price to Tang. Book | 0.58 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.18 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -24.26% | ||
| Return on Equity | -24.25% | ||
| Operating Margin | -104.11% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 171.13 | 37.41 | 40.91 | 250.01 | 80 | 66.14 | 67.5 | -5.18% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Voyager Therapeutics, Inc. is a biotechnology company engaged in leveraging the power of human genetics to modify the course of neurological diseases. The Company’s pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of its programs are derived from its Tropism Redirection of AAV by Cell-type-specific Expression of RNA (TRACER) adeno-associated virus (AAV) capsid discovery platform, which is used to generate capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs includes Anti-Tau Antibody (VY7523), Tau Silencing Gene Therapy (VY1706), SOD1 Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program and others.
Directors
- Michael Higgins CHM (58)
- Julie Burek CFO (47)
- Robin Swartz COO (51)
- Robert Hesslein SVP (68)
- Glenn Pierce CSO (65)
- Steven Paul DRC (70)
- Alfred Sandrock DRC (63)
- James Geraghty IND (67)
- Steven Hyman IND (68)
- Mark Levin IND (70)
- Nancy Vitale IND (50)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 19th, 2013
- Public Since
- November 11th, 2015
- No. of Shareholders
- 10
- No. of Employees
- 172
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 55,206,885
- Address
- 75 Hayden Avenue, LEXINGTON, 02421
- Web
- https://www.voyagertherapeutics.com/
- Phone
- +1 8572595340
- Auditors
- Ernst & Young LLP
Upcoming Events for VYGR
Voyager Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Voyager Therapeutics Inc Earnings Release
Similar to VYGR
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Voyager Therapeutics share price?
As of Today at 24:02 UTC, shares in Voyager Therapeutics are trading at $3.16. This share price information is delayed by 15 minutes.
How has the Voyager Therapeutics share price performed this year?
Shares in Voyager Therapeutics last closed at $3.16 and the price had moved by -59.17% over the past 365 days. In terms of relative price strength the Voyager Therapeutics share price has underperformed the S&P500 Index by -61.61% over the past year.
What are the analyst and broker recommendations for Voyager Therapeutics?
The overall consensus recommendation for Voyager Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Voyager Therapeutics dividend yield?
Voyager Therapeutics does not currently pay a dividend.
Does Voyager Therapeutics pay a dividend?
Voyager Therapeutics does not currently pay a dividend.
When does Voyager Therapeutics next pay dividends?
Voyager Therapeutics does not currently pay a dividend.
How do I buy Voyager Therapeutics shares?
To buy shares in Voyager Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Voyager Therapeutics?
As of the previous close price of $3.16, shares in Voyager Therapeutics had a market capitalisation of $174.45m.
Where are Voyager Therapeutics shares listed?
Here are the trading details for Voyager Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: VYGR
What kind of share is Voyager Therapeutics?
Based on an overall assessment of its quality, value and momentum Voyager Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Voyager Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Voyager Therapeutics is $13.63. That is 331.33% above the last closing price of $3.16.
Analysts covering Voyager Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.67 for the next financial year.
Find out moreWhat is the trend in the Voyager Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Voyager Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -56.61%.
As of the last closing price of $3.16, shares in Voyager Therapeutics were trading -46.94% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Voyager Therapeutics PE Ratio?
The Voyager Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.16.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Voyager Therapeutics?
Voyager Therapeutics' management team is headed by:
- Michael Higgins - CHM
- Julie Burek - CFO
- Robin Swartz - COO
- Robert Hesslein - SVP
- Glenn Pierce - CSO
- Steven Paul - DRC
- Alfred Sandrock - DRC
- James Geraghty - IND
- Steven Hyman - IND
- Mark Levin - IND
- Nancy Vitale - IND